Advancements in antibody engineering and recent clinical successes have led to enthusiasm for the development of bispecific modalities with the unique ability to bind to two distinct antigens or two different epitopes on the same antigen. T‐cell directing/engaging bispecific agents (TDBs), in particular, are rapidly becoming an important class of molecules in oncology drug development. These agents enhance recruitment of effector cells (e.g., cytotoxic T‐cells) to tumor‐associated/specific antigens for targeted cell killing. Like other T‐cell engaging therapies, TDBs engage the host’s T‐cells thereby driving deep and durable clinical response beyond treatment termination. However, unlike chimeric antigen receptor T‐cell therapies, which take weeks from collection of patients’ T‐cells to availability of treatment product, TDBs are available off‐the‐shelf.
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Karen Geary
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret
Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys